お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙:経皮吸収型スコポラミン製剤の世界市場 - 産業分析・市場規模・市場シェア・成長率・各種動向・将来予測 (2016-2024年)
市場調査レポート
商品コード
493957

経皮吸収型スコポラミン製剤の世界市場 - 産業分析・市場規模・市場シェア・成長率・各種動向・将来予測 (2016-2024年)

Transdermal Scopolamine Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

出版日: | 発行: Transparency Market Research | ページ情報: 英文 103 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=109.93円
経皮吸収型スコポラミン製剤の世界市場 - 産業分析・市場規模・市場シェア・成長率・各種動向・将来予測 (2016-2024年)
出版日: 2017年04月05日
発行: Transparency Market Research
ページ情報: 英文 103 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、世界の経皮吸収型スコポラミン製剤の市場を調査し、市場および製品の定義と概要、地域別の処方率、市場への各種影響因子および市場機会の分析、地域・主要国別の動向と市場規模の推移と予測、競合環境、主要企業のプロファイルなどをまとめています。

第1章 序章

第2章 前提因子・調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

  • イントロダクション
  • 市場概要
  • 主な市場指標
  • 市場力学
    • 成長推進因子
    • 成長抑制因子
    • 市場機会
  • 世界市場の分析・予測
  • ポーターのファイブフォース分析
  • バリューチェーン分析
  • 市場の展望
  • 企業シェア分析
  • スコポラミン製品の処方率:地域別
  • パイプライン分析

第5章 市場分析・予測:地域別

  • 主要調査結果
  • 政策・法規制
  • 市場予測
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場の魅力の分析

第6章 北米市場の分析・予測

  • イントロダクション
    • 主要調査結果
    • 政策・法規制
    • 価格動向分析
    • 主要動向
  • 市場予測:国別
    • 米国
    • カナダ
  • 市場の魅力の分析

第7章 欧州市場の分析・予測

  • イントロダクション
    • 主要調査結果
    • 政策・法規制
    • 価格動向分析
    • 主要動向
  • 市場予測:国別
    • ドイツ
    • フランス
    • 英国
    • スペイン
    • イタリア
    • その他
  • 市場の魅力の分析

第8章 アジア太平洋市場の分析・予測

  • イントロダクション
    • 主要調査結果
    • 政策・法規制
    • 価格動向分析
    • 主要動向
  • 市場予測:国別
    • 日本
    • 中国
    • インド
    • オーストラリア
    • その他
  • 市場の魅力の分析

第9章 ラテンアメリカ市場の分析・予測

  • イントロダクション
    • 主要調査結果
    • 政策・法規制
    • 価格動向分析
    • 主要動向
  • 市場予測:国別
    • ブラジル
    • メキシコ
    • その他
  • 市場の魅力の分析

第10章 中東・アフリカ市場の分析・予測

  • イントロダクション
    • 主要調査結果
    • 政策・法規制
    • 価格動向分析
    • 主要動向
  • 市場予測:国別
    • GCC諸国
    • 南アフリカ
    • その他
  • 市場の魅力の分析

第11章 競合環境

  • 競合マトリックス
  • 企業プロファイル
    • Baxter International Inc.
    • GlaxoSmithKline plc
    • Novartis AG
    • Perrigo Company plc.
    • Caleb Pharmaceuticals, Inc.
    • Myungmoon Pharma Co. LTD.

第12章 総論

図表

目次

Global Transdermal Scopolamine Market: Overview

Scopolamine is an alkaloid, a secondary metabolite produced by plants of nightshade family such as henbane, Datura, Duboisia, etc. Scopolamine is used to treat motion sickness, and post-operative and anesthesia induced nausea and vomiting. It is often used to treat gastrointestinal spasm, irritable bowel syndrome and eye inflammation. Scopolamine is also used for nausea and vomiting prevention in chemotherapy for cancer treatment. Scopolamine can be administered orally as tablets or syrups, intravenously as injections and solutions, or as transdermal in form of patch or gel. Transdermal scopolamine is a scopolamine patch used to treat motion sickness and post-operative nausea and vomiting. Transdermal scopolamine available today are reservoir patches which can be used for up to 3 days. These patches are applied at back side of ear. These patches are applied 20 minutes to 4 hours before the intended use such as travel, surgery etc.

The first transdermal scopolamine patch was approved in 1979, manufactured by Alza Corporation and marketed by Novartis AG by brand name Transderm Scop. There are very few generics approved by FDA for Transderm Scop, which makes the market less competitive. Though there are few small players operating on regional level, however they hold a meager share in global transdermal scopolamine market. The global market for transdermal scopolamine is expected to grow at CAGR of 6.7% over the forecast period from 2016 to 2024. The launch of recently approved generics and projected expansion of international players is expected to drive the growth for this market. Moreover many of the industry players and researchers are investing on development of new transdermal scopolamine products.

Transdermal scopolamine is a preferred choice to treat motion sickness owing to its ease in administration, cost effectiveness and availability. Rise in number of travelers across globe is expected to drive the growth for transdermal scopolamine market over the forecast period. Moreover some of the industry players and researchers are investing on development of improved transdermal scopolamine patch on material, adhesion, drug bioavailability and other aspects. Expected introduction of such improved products coupled with launch of new entrants is expected to trigger the growth for transdermal scopolamine market. However there are few concern factors with transdermal scopolamine such as adverse effects, specifically the withdrawal symptoms which are anticipated to restrain growth.

Global Transdermal Scopolamine Market: Regional Outlook

Geographically, the transdermal scopolamine market has been segmented into five regions: North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. These regions have been further segmented to country and sub-regional level. North America is expected to contribute largest share in global transdermal scopolamine market owing to high number of travelers, well established healthcare industry. Europe is expected to hold second position in global transdermal scopolamine market with growing number of surgeries and rising number of travelers.

The competition matrix section included in the report is likely to assist the existing players to increase their market shares and new companies to establish their presence in the global transdermal scopolamine market.

Companies Mentioned in the Report

The report also profiles major players in the market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include Novartis AG, GlaxoSmithKline plc, Baxter International Inc., Perrigo Company plc, Caleb Pharmaceuticals, Inc., and Myungmoon Pharma Co. Ltd.

The global transdermal scopolamine market has been segmented as follows:

By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Table of Contents

Chapter 1: Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

Chapter 2: Assumptions and Research Methodology

Chapter 3: Executive Summary: Global Transdermal Scopolamine Market

Chapter 4: Market Overview

  • 4.1. Introduction
    • 4.1.1. Scopolamine Indications
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Market Overview
  • 4.3. Key Market Indicators
  • 4.4. Market Dynamics
    • 4.4.1. Drivers
    • 4.4.2. Restraints
    • 4.4.3. Opportunities
  • 4.5. Global Transdermal Scopolamine Market Analysis and Forecast, 2016 - 2024
    • 4.5.1. Market Revenue Projections (US$ Mn)
  • 4.6. Porter's five forces analysis
  • 4.7. Value Chain Analysis
  • 4.8. Market Outlook
  • 4.9. Global Company Share Analysis - 2016 (Estimated)
  • 4.10. Scopolamine Product Prescription Rate by Region (%)
    • 4.10.1. Oral
    • 4.10.2. Injections
    • 4.10.3. Transdermal / Patch
  • 4.11. Pipeline Analysis - Transdermal Scopolamine

Chapter 5: Global Transdermal Scopolamine Market Analysis and Forecasts, By Region

  • 5.1. Key Findings
  • 5.2. Policies and Regulations
  • 5.3. Market Size (US$ Mn) Forecast By Region
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. Asia Pacific
    • 5.3.4. Latin America
    • 5.3.5. Middle East and Africa
  • 5.4. Market Attractiveness By Region

Chapter 6: North America Transdermal Scopolamine Market Analysis and Forecast

  • 6.1. Introduction
    • 6.1.1. Key Findings
    • 6.1.2. Policies and Regulations
    • 6.1.3. Price Trend Analysis
    • 6.1.4. Key Trends
  • 6.2. Market Size (US$ Mn) Forecast, By Country
    • 6.2.1. U.S.
    • 6.2.2. Canada
  • 6.3. Market Attractiveness Analysis By Country

Chapter 7: Europe Transdermal Scopolamine Market Analysis and Forecast

  • 7.1. Introduction
    • 7.1.1. Key Findings
    • 7.1.2. Policies and Regulations
    • 7.1.3. Price Trend Analysis
    • 7.1.4. Key Trends
  • 7.2. Market Size (US$ Mn) Forecast, By Country
    • 7.2.1. Germany
    • 7.2.2. France
    • 7.2.3. U.K.
    • 7.2.4. Spain
    • 7.2.5. Italy
    • 7.2.6. Rest of Europe
  • 7.3. Market Attractiveness Analysis By Country

Chapter 8: Asia Pacific Transdermal Scopolamine Market Analysis and Forecast

  • 8.1. Introduction
    • 8.1.1. Key Findings
    • 8.1.2. Policies and Regulations
    • 8.1.3. Price Trend Analysis
    • 8.1.4. Key Trends
  • 8.2. Market Size (US$ Mn) Forecast, By Country
    • 8.2.1. Japan
    • 8.2.2. China
    • 8.2.3. India
    • 8.2.4. Australia
    • 8.2.5. Rest of Asia Pacific
  • 8.3. Market Attractiveness Analysis By Country

Chapter 9: Latin America Transdermal Scopolamine Market Analysis and Forecast

  • 9.1. Introduction
    • 9.1.1. Key Findings
    • 9.1.2. Policies and Regulations
    • 9.1.3. Price Trend Analysis
    • 9.1.4. Key Trends
  • 9.2. Market Size (US$ Mn) Forecast, By Country
    • 9.2.1. Brazil
    • 9.2.2. Mexico
    • 9.2.3. Rest of Latin America
  • 9.3. Market Attractiveness Analysis By Country

Chapter 10: Middle East & Africa Transdermal Scopolamine Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
    • 10.1.2. Policies and Regulations
    • 10.1.3. Price Trend Analysis
    • 10.1.4. Key Trends
  • 10.2. Market Size (US$ Mn) Forecast, By Country
    • 10.2.1. GCC Countries
    • 10.2.2. South Africa
    • 10.2.3. Rest of Middle East and Africa
  • 10.3. Market Attractiveness Analysis By Country

Chapter 11: Competition Landscape

  • 11.1. Transdermal Scopolamine Market - Competition Matrix (By Tier and Size of companies) (2015)
  • 11.2. Company Profiles (Details - Overview, Financials, Recent Developments, Strategy)
    • 11.2.1. Baxter International Inc.
      • 11.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 11.2.1.2. Product Portfolio
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Financial Overview
      • 11.2.1.5. Strategic Overview
    • 11.2.2. GlaxoSmithKline plc
      • 11.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 11.2.2.2. Product Portfolio
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Financial Overview
      • 11.2.2.5. Strategic Overview
    • 11.2.3. Novartis AG
      • 11.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 11.2.3.2. Product Portfolio
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Financial Overview
      • 11.2.3.5. Strategic Overview
    • 11.2.4. Perrigo Company plc.
      • 11.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 11.2.4.2. Product Portfolio
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Financial Overview
      • 11.2.4.5. Strategic Overview
    • 11.2.5. Caleb Pharmaceuticals, Inc.
      • 11.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 11.2.5.2. Product Portfolio
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Financial Overview
      • 11.2.5.5. Strategic Overview
    • 11.2.6. Myungmoon Pharma Co. LTD.
      • 11.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 11.2.6.2. Product Portfolio
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Financial Overview
      • 11.2.6.5. Strategic Overview

Chapter 12: Key Take Away

List of Figures

  • Figure 01: Global Transdermal Scopolamine Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2014-2024
  • Figure 02: Global Transdermal Scopolamine Market Share Analysis, by Company, 2016 (Estimated)
  • Figure 03: Global Scopolamine Product Prescription Share, by Region
  • Figure 04: Global Transdermal Scopolamine Market Value Share Analysis, by Region, 2015 and 2024
  • Figure 05: Global Transdermal Scopolamine Market Attractiveness Analysis, by Region
  • Figure 06: North America Transdermal Scopolamine Market Value Share Analysis, by Country, 2015 and 2024
  • Figure 07: North America Transdermal Scopolamine Market Attractiveness Analysis, by Country
  • Figure 08: Europe Transdermal Scopolamine Market Value Share Analysis, by Country / Sub-region, 2015 and 2024
  • Figure 09: Europe Transdermal Scopolamine Market Attractiveness Analysis, by Country / Sub-region
  • Figure 10: Asia Pacific Transdermal Scopolamine Market Value Share Analysis, by Country / Sub-region, 2015 and 2024
  • Figure 11: Asia Pacific Transdermal Scopolamine Market Attractiveness Analysis, by Country / Sub-region
  • Figure 12: Latin America Transdermal Scopolamine Market Value Share Analysis, by Country / Sub-region, 2015 and 2024
  • Figure 13: Latin America Transdermal Scopolamine Market Attractiveness Analysis, by Country / Sub-region
  • Figure 14: MEA Transdermal Scopolamine Market Value Share Analysis, by Country / Sub-region, 2015 and 2024
  • Figure 15: Middle East & Africa Transdermal Scopolamine Market Attractiveness Analysis, by Country / Sub-region

List of Tables

  • Table 01: Global Transdermal Scopolamine Market Size (US$ Mn) Forecast, 2015-2024
  • Table 02: Global Transdermal Scopolamine Market Size (US$ Mn) Forecast, by Region, 2015-2024
  • Table 03: North America Transdermal Scopolamine Market Size (US$ Mn) Forecast, by Country,
  • Table 04: Europe Transdermal Scopolamine Market Size (US$ Mn) Forecast, by Country / Sub-region, 2015-2024
  • Table 05: Asia Pacific Transdermal Scopolamine Market Size (US$ Mn) Forecast, by Country / Sub-region, 2015-2024
  • Table 06: Latin America Transdermal Scopolamine Market Size (US$ Mn) Forecast, by Country / Sub-region, 2015-2024
  • Table 07: Middle East & Africa Transdermal Scopolamine Market Size (US$ Mn) Forecast, by Country / Sub-region, 2015-2024
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.